keyword
MENU ▼
Read by QxMD icon Read
search

Stem cells, hematopoietic stem cell transplantation, apheresis

keyword
https://www.readbyqxmd.com/read/27859332/patients-outcome-after-rescue-plerixafor-administration-for-autologous-stem-cell-mobilization-a-single-center-retrospective-analysis
#1
Silvia Spoerl, Robert Peter, Dagmar Wäscher, Katharina Götze, Mareike Verbeek, Christian Peschel, Angela M Krackhardt
BACKGROUND: Plerixafor is predominantly used for patients mobilizing inadequate stem cell numbers for autologous transplantation after stimulation with granulocyte-colony-stimulating factor (G-CSF). STUDY DESIGN AND METHODS: We here report on 300 patients undergoing stem cell mobilization with G-CSF, among them 36 poor mobilizers (CD34+ cell counts < 50 × 10(6) /L blood) receiving G-CSF alone and 49 receiving G-CSF in combination with plerixafor for rescue intervention...
November 18, 2016: Transfusion
https://www.readbyqxmd.com/read/27846612/effect-of-high-dose-plerixafor-on-cd34-cells-mobilization-in-healthy-stem-cell-donors-results-of-a-randomized-crossover-trial
#2
Jeremy Pantin, Enkhtsetseg Purev, Xin Tian, Lisa Cook, Theresa Donohue-Jerussi, Elena Cho, Robert Reger, Matthew Hsieh, Hanh Khuu, Gary Calandra, Nancy L Geller, Richard W Childs
Hematopoietic stem cells can be mobilized from healthy donors using single-agent plerixafor without G-CSF, and following allogeneic transplantation, can result in sustained donor derived hematopoiesis. However, when a single dose of plerixafor is administered at a conventional 240 mg/kg dose, approximately one third of donors will fail to mobilize the minimally acceptable dose of CD34+ cells needed for allogeneic transplantation. We conducted an open-label, randomized trial to assess the safety and activity of high-dose (480 mg/kg) plerixafor in CD34+ cell mobilization in healthy donors...
October 20, 2016: Haematologica
https://www.readbyqxmd.com/read/27792717/-comparison-of-the-effectiveness-of-hematopoietic-cell-mobilization-with-chemotherapy-and-filgrastim-versus-filgrastim-alone-for-autologous-transplant-in-patients-with-lymphoma
#3
César Homero Gutiérrez-Aguirre, Fernando De la Garza-Salazar, Olga Cantú-Rodríguez, Óscar González-Llano, José C Jaime-Pérez, Consuelo Mancias-Guerra, Ricardo García-Sepúlveda, Rosario Salazar-Riojas, David Gómez-Almaguer
INTRODUCTION: Autologous hematopoietic stem cell transplantation is the treatment of choice for high-risk Hodgkin's lymphoma and non-Hodgkin's lymphoma. OBJECTIVE: Compare the capacity to mobilize CD34+ cells for autologous hematopoietic stem cell transplantation using schemes with chemotherapy and without chemotherapy plus filgrastim in patients diagnosed with Hodgkin's lymphoma or non-Hodgkin's lymphoma. MATERIAL AND METHODS: The clinical records of patients with Hodgkin's lymphoma or non-Hodgkin's lymphoma who received an autologous hematopoietic stem cell transplant were analyzed retrospectively...
October 2016: Gaceta Médica de México
https://www.readbyqxmd.com/read/27746781/comparative-analysis-of-clinical-scale-ifn-%C3%AE-positive-t-cell-enrichment-using-partially-and-fully-integrated-platforms
#4
Christoph Priesner, Ruth Esser, Sabine Tischer, Michael Marburger, Krasimira Aleksandrova, Britta Maecker-Kolhoff, Hans-Gert Heuft, Lilia Goudeva, Rainer Blasczyk, Lubomir Arseniev, Ulrike Köhl, Britta Eiz-Vesper, Stephan Klöß
BACKGROUND AND AIMS: The infusion of enriched CMV-specific donor T-cells appears to be a suitable alternative for the treatment of drug-resistant CMV reactivation or de novo infection after both solid organ and hematopoietic stem cell transplantation. Antiviral lymphocytes can be selected from apheresis products using the CliniMACS Cytokine-Capture-System(®) either with the well-established CliniMACS(®) Plus (Plus) device or with its more versatile successor CliniMACS Prodigy(®) (Prodigy)...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27688610/newly-established-stem-cell-transplant-program-100-days-follow-up-of-patients-and-its-comparison-with-published-indian-literature
#5
Aseem Kumar Tiwari, Dinesh Arora, Ravi C Dara, Pranav Dorwal, Nitin Sood, Ruchira Misra, Sunil Kumar Gupta, Vimarsh Raina, Ashok Kumar Vaid
BACKGROUND: Hematopoietic progenitor stem cell transplantation (HPSCT) is used as a standard treatment option to improve outcome in hematological and nonhematological disorders. It is important for new HPSCT program to look at its patient outcome data and compare it with the published data to evaluate the efficacy of program. AIMS: The aim was to compile and collate the patient outcome data of HPSCT and compare with published reports. MATERIALS AND METHODS: Patient demographics, indications, stem cell harvest by apheresis, dose collected, infusion, engraftment, and follow-up data were collected from hospital information system from 2010 to 2013 in a tertiary care hospital...
July 2016: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/27665155/factors-affecting-the-cd34-cell-yields-from-the-second-donations-of-healthy-donors-the-steady-state-lymphocyte-count-is-a-good-predictive-factor
#6
Zhi-Ping Guo, Tao Wang, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Xiao-Jun Huang, Ying-Jun Chang
BACKGROUND: A second allogeneic hematopoietic stem-cell transplantation and donor lymphocyte infusion using cells from the same donor is a therapeutic option in the case of stem-cell graft failure or disease relapse, but little is known about the factors associated with the CD34(+) cell yields from second donations. METHODS: One-hundred healthy donors who underwent a second mobilization treatment and peripheral blood stem-cell (PBSC) collection were studied. For both mobilization processes, 5 µg of granulocyte colony-stimulating factor per kg per day was administered...
August 26, 2016: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/27536190/plerixafor-for-autologous-stem-cell-mobilization-and-transplantation-for-patients-in-ontario
#7
C T Kouroukis, N P Varela, C Bredeson, J Kuruvilla, A Xenocostas
BACKGROUND: High-dose chemotherapy with autologous stem-cell transplantation (asct) is an accepted part of standard therapy for patients with hematologic malignancies. Usually, stem-cell mobilization uses granulocyte colony-stimulating factor (g-csf); however, some patients are not able to be mobilized with chemotherapy and g-csf, and such patients could be at higher risk of failing mobilization. Plerixafor is a novel mobilization agent that is absorbed quickly after subcutaneous injection and, at the recommended dose of 0...
August 2016: Current Oncology
https://www.readbyqxmd.com/read/27497701/expanded-and-armed-natural-killer-cells-for-cancer-treatment
#8
Noriko Shimasaki, Elaine Coustan-Smith, Takahiro Kamiya, Dario Campana
The capacity of natural killer (NK) cells to recognize and kill transformed cells suggests that their infusion could be used to treat cancer. It is difficult to obtain large numbers of NK cells ex vivo by exposure to cytokines alone but the addition of stimulatory cells to the cultures can induce NK cell proliferation and long-term expansion. Some of these methods have been validated for clinical-grade application and support clinical trials testing feasibility and safety of NK cell administration. Early data indicate that ex vivo expansion of NK cells from healthy donors or from patients with cancer is robust, allowing multiple infusions from a single apheresis...
November 2016: Cytotherapy
https://www.readbyqxmd.com/read/27491794/variable-resistance-to-freezing-and-thawing-of-cd34-positive-stem-cells-and-lymphocyte-subpopulations-in-leukapheresis-products
#9
Christina Berens, Annkristin Heine, Jens Müller, Stefanie Andrea Erika Held, Karin Mayer, Peter Brossart, Johannes Oldenburg, Bernd Pötzsch, Dominik Wolf, Heiko Rühl
BACKGROUND AIMS: Leukapheresis products for hematopoietic stem cell transplantation can be cryopreserved for various indications. Although it is known that CD34(+) cells tolerate cryopreservation well, a significant loss of CD3(+) cells has been observed, which has been ascribed to several factors, including transport, storage conditions and granulocyte-colony stimulating factor (G-CSF) administration. METHODS: To assess the tolerance of CD34(+) cells and lymphocyte subpopulations for cryopreservation and thawing, the post-thaw recoveries of CD34(+) cells, CD3(+)CD4(+) cells, CD3(+)CD8(+) cells, CD19(+) cells and CD16(+)CD56(+) cells were determined in 90 cryopreserved apheresis products, among which 65 were from G-CSF-mobilized donors, and 34 from unrelated donors that underwent transport before cryopreservation at our center...
October 2016: Cytotherapy
https://www.readbyqxmd.com/read/27214069/bendamustine-etoposide-and-dexamethasone-to-mobilize-peripheral-blood-hematopoietic-stem-cells-for-autologous-transplantation-in-patients-with-multiple-myeloma
#10
D J Green, W I Bensinger, L A Holmberg, T Gooley, B G Till, L E Budde, J M Pagel, S L Frayo, J E Roden, L Hedin, O W Press, A K Gopal
Chemotherapeutic agents without cross-resistance to prior therapies may enhance PBSC collection and improve patient outcomes by exacting a more potent direct antitumor effect before autologous stem cell transplant. Bendamustine has broad clinical activity in transplantable lymphoid malignancies, but concern remains over the potential adverse impact of this combined alkylator-nucleoside analog on stem cell mobilization. We performed a prospective, nonrandomized phase II study including 34 patients with multiple myeloma (MM) (n=34; International Staging System (ISS) stages I (35%), II (29%) and III (24%); not scored (13%)) to evaluate bendamustine's efficacy and safety as a stem cell mobilizing agent...
October 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27179747/imaging-and-1-day-kinetics-of-intracoronary-stem-cell-transplantation-in-patients-with-idiopathic-dilated-cardiomyopathy
#11
Luka Lezaic, Aljaz Socan, Petra Kolenc Peitl, Gregor Poglajen, Matjaz Sever, Marko Cukjati, Peter Cernelc, Bojan Vrtovec
BACKGROUND: Stem cell transplantation is an emerging method of treatment for patients with cardiovascular disease. There are few studies completed or ongoing on stem cell therapy in patients with idiopathic dilated cardiomyopathy (IDCM). Information on stem cell homing and distribution in the myocardium after transplantation might provide important insight into effectiveness of transplantation procedure. AIM: To assess early engraftment, retention and migration of intracoronarily transplanted stem cells in the myocardium of patients with advanced dilated cardiomyopathy of non-ischaemic origin using stem cell labeling with (99m)Tc-exametazime (HMPAO)...
July 2016: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/27103979/the-high-effect-of-chemomobilization-with-high-dose-etopside-granulocyte-colony-stimulating-factor-in-autologous-hematopoietic-peripheral-blood-stem-cell-transplantation-a-single-center-experience
#12
Şebnem Izmir Güner, Mustafa Teoman Yanmaz, Ahmet Selvi, Cigdem Usul
Autologous hematopoietic stem cell transplantation (auto-HSCT) provides hematopoietic support after high-dose chemotherapy and is the standard of care for patients with multiple myeloma (MM), chemo sensitive relapsed high or intermediate grade non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). However, yields of hematopoietic stem cells vary greatly between patients, and the optimal strategy to mobilize hematopoietic stem cells into peripheral blood for collection has not been defined yet. We investigated the efficacy and safety of chemo mobilization with an intermediate dose etoposide (VP-16; 200 mg/m(2) on days 1-3) and granulocyte-colony stimulating factor (G-CSF)(5 µg/kg twice daily from day 4 through the final day of collection)...
March 17, 2016: Hematology Reports
https://www.readbyqxmd.com/read/27090958/haploidentical-natural-killer-cells-infused-before-allogeneic-stem-cell-transplantation-for-myeloid-malignancies-a-phase-i-trial
#13
Dean A Lee, Cecele J Denman, Gabriela Rondon, Glenda Woodworth, Julianne Chen, Tobi Fisher, Indreshpal Kaur, Marcelo Fernandez-Vina, Kai Cao, Stefan Ciurea, Elizabeth J Shpall, Richard E Champlin
Allogeneic stem cell transplantation is an effective treatment for high-risk myeloid malignancies, but relapse remains the major post-transplantation cause of treatment failure. Alloreactive natural killer (NK) cells mediate a potent antileukemic effect and may also enhance engraftment and reduce graft-versus-host disease (GVHD). Haploidentical transplantations provide a setting in which NK cell alloreactivity can be manipulated, but they are associated with high rates of GVHD. We performed a phase I study infusing escalating doses of NK cells from an HLA haploidentical-related donor-selected for alloreactivity when possible-as a component of the preparative regimen for allotransplantation from a separate HLA-identical donor...
July 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27011680/autologous-peripheral-blood-stem-cell-harvest-collection-efficiency-and-factors-affecting-it
#14
Aseem K Tiwari, Prashant Pandey, Harini Subbaraman, Rahul Bhargava, Ganesh Rawat, Shivani Madiraju, Vimarsh Raina, Richa Bhargava
BACKGROUND: Harvest of hematopoietic progenitor cells via leukapheresis is being used increasingly for transplants in India. Adequate yield of cells per kilogram body weight of recipient is required for successful engraftment. Collection efficiency (CE) is an objective quality parameter used to assess the quality of leukapheresis program. In this study, we calculated the CE of the ComTec cell separator (Fresenius Kabi, Germany) using two different formulae (CE1 and CE2) and analyzed various patient and procedural factors, which may affect it...
January 2016: Asian Journal of Transfusion Science
https://www.readbyqxmd.com/read/26901572/safety-and-efficacy-of-hematopoietic-stem-cells-mobilization-in-patients-with-multiple-sclerosis
#15
Sławomira Kyrcz-Krzemień, Grzegorz Helbig, Karolina Torba, Anna Koclęga, Małgorzata Krawczyk-Kuliś
Introduction Multiple sclerosis (MS) is a T-cell-mediated chronic inflammatory disorder of the central nervous system. Several agents have been approved for treatment of MS, however their efficacy is limited and short term. Autologous hematopoietic stem cell (HSC) transplantation may remain an encouraging option for some MS patients who failed prior conventional treatment. Objective To assess the safety and effectiveness of HSCs mobilization in patients with MS. Material and methods Thirty-nine patients (20 females, 19 males) with relapsing-remitting MS at median age of 40 years (range 25-63) were included in this study...
February 22, 2016: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/26812941/donors-health-state-the-year-after-peripheral-haematopoietic-progenitor-cell-collection-a-prospective-follow-up-study-in-related-and-unrelated-donors-compared-to-first-time-platelet-donors
#16
I Bank, J C Wiersum-Osselton, S M Van Walraven, T Netelenbos, M Fechter, T Marijt-van der Kreek, B M A M Bär, J G Van der Bom, A Brand
Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral haematopoietic progenitor cells collected by apheresis (HPC-A) are the most common source used for allogeneic hematopoietic stem cell transplantation (HSCT). Retrospective short and long-term donor follow-up studies show very low risks of serious complications and do not report compelling evidence of increased cancer occurrence. Some studies reported a prolonged period of leucopenia without an obvious association with infectious complications...
December 2016: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/26643030/improved-prediction-of-cd34-cell-yield-before-peripheral-blood-hematopoietic-progenitor-cell-collection-using-a-modified-target-value-tailored-approach
#17
Dawn Sheppard, Jason Tay, Douglas Palmer, Anargyros Xenocostas, Christina Doulaverakis, Lothar Huebsch, Sheryl McDiarmid, Alan Tinmouth, Ranjeeta Mallick, Lisa Martin, Paul Birch, Linda Hamelin, David Allan, Christopher Bredeson
The most commonly used stem cell source for both autologous and allogeneic transplantation is mobilized peripheral blood hematopoietic progenitor cells collected by apheresis. In the 1990s, an Italian group used the correlation between the preapheresis peripheral blood CD34+ cell count and the final number of CD34+ cells collected to devise a formula for "target value-tailored" (TVT) apheresis. Using local patient data, the Canadian Blood Services Stem Cell Laboratory created a similar model to determine the blood volume to process during apheresis collection...
April 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/26390165/donor-derived-cd19-targeted-t-cells-in-allogeneic-transplants
#18
REVIEW
Chiara Francesca Magnani, Andrea Biondi, Ettore Biagi
PURPOSE OF REVIEW: Allogeneic hematopoietic stem cell transplantation (HSCT) is still partially ineffective in curing high-risk hematological malignancies, with estimates of relapse rates ranging from 40 to 50%. The purpose of this review is to discuss the emerging therapeutic options for patients with relapsed disease following HSCT based on adoptive immunotherapy using donor-derived T cells genetically engineered to express CD19-specific chimeric antigen receptors (CARs). RECENT FINDINGS: Adoptive cell therapy (ACT) with CAR-modified T cells represents an attractive therapeutic option for further enhancing the graft-versus-leukemia effect...
November 2015: Current Opinion in Hematology
https://www.readbyqxmd.com/read/26340986/cyclophosphamide-plus-granulocyte-colony-stimulating-factor-for-hematopoietic-stem-cell-mobilization-in-patients-with-multiple-myeloma
#19
Tung-Liang Lin, Po-Nan Wang, Ming-Chung Kuo, Yu-Hsing Hung, Hung Chang, Tzung-Chih Tang
We retrospectively reviewed the results of cyclophosphamide (3 g/m(2) ), doxorubicin and dexamethasone plus granulocyte-colony stimulating factor (G-CSF) (ID-CY/DOX group), low-dose cyclophosphamide (2 g/m(2) ) plus G-CSF (LD-CY group) and G-CSF alone (G-CSF group) for stem cell mobilization in patients with multiple myeloma. A total of 89 patients with 93 mobilizations were included. Apheresis was started when total white blood cell (WBC) count >10 × 10(9) /L for ID-CY/DOX and LD-CY groups and after eight doses of G-CSF (5 μg/kg twice daily) for G-CSF group...
October 2016: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/26330136/safety-and-efficacy-of-hematopoietic-stem-cells-mobilization-in-patients-with-multiple-sclerosis
#20
Sławomira Kyrcz-Krzemień, Grzegorz Helbig, Karolina Torba, Anna Koclęga, Małgorzata Krawczyk-Kuliś
INTRODUCTION: Multiple sclerosis (MS) is a T-cell-mediated chronic inflammatory disorder of the central nervous system. Several agents have been approved for the treatment of MS; however, their efficacy is limited and short term. Autologous hematopoietic stem cell (HSC) transplantation may remain an encouraging option for some MS patients who failed prior conventional treatment. Objective To assess the safety and effectiveness of HSCs mobilization in patients with MS. MATERIAL AND METHODS: Thirty-nine patients (20 females and 19 males) with relapsing-remitting MS at median age of 40 years (range: 25-63) were included in this study...
January 2016: Hematology (Amsterdam, Netherlands)
keyword
keyword
47612
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"